Hyloris (HYL) | Stock Overview & Key Data
Hyloris Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €19.10 on January 3, 2022
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Financial Highlights
Quarter Income Flow
Jun 30, 2020
Annual Income Flow
2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Hyloris
HYL
|
152.32M Mid-cap | -5.80% | -9.77% | -21.24% | -20.97% | -34.40% | -18.10% | -59.05% | -65.07% | -55.10% | -55.10% | -55.10% |
|
UCB S.A
UCB
|
50.14B Large-cap | -0.69% | 9.37% | 1.69% | 8.86% | 10.67% | 68.19% | 220.47% | 222.73% | 332.23% | 618.13% | 618.13% |
|
Argenx SE
ARGX
|
41.43B Large-cap | -0.26% | 9.81% | 24.18% | 24.18% | 24.18% | 29.01% | 29.01% | 29.01% | 29.01% | 29.01% | 29.01% |
|
Onward Medical N.V
ONWD
|
204.41M Mid-cap | -3.62% | -3.97% | -26.92% | -34.00% | -39.41% | -37.17% | -55.89% | -79.43% | -79.43% | -79.43% | -79.43% |
| N/A | -1.22% | 14.47% | 5.09% | 6.07% | 7.58% | 85.71% | 225.88% | 200.37% | 364.29% | 681.77% | 681.77% | |
|
European Medical
ALEMS
|
20.74M Small-cap | 1.63% | 2.04% | 1.01% | -7.41% | 6.84% | 6.38% | -16.39% | -95.91% | -99.74% | -99.78% | -99.78% |
Ownership & Short Interest
Calculate Your Hyloris Investment Returns
Long-Term Investment Performance Analysis
Hyloris stock price in Jun 2020 was €10.58, A €1,000.00 lump sum investment in Hyloris made 6 years ago would be worth approximately €445.18 today, representing a negative return of -55.48%. This translates to an annualized return (CAGR) of -12.70%.
5 Years 11 Months Investment Scenario (Jun 2020 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is HYL's 52-week high and low?
- In the last 52 weeks, Hyloris reached a high of €8.40 (on January 14, 2026) and a low of €4.51 (on March 30, 2026).
- What is the market cap and P/E ratio for HYL?
- Curious about Hyloris's size and valuation? Its market capitalization stands at 152.32M. When it comes to valuation, the P/E ratio (trailing twelve months) is -23.65, and the forward P/E (looking ahead) is 10.76.
- Does HYL pay dividends? If so, what's the yield?
- As for dividends, Hyloris isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Hyloris's main competitors or similar companies to consider before investing?
When looking at Hyloris, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return UCB S.A
UCB50.14B Healthcare Biotechnology 68.19% 220.47% Argenx SE
ARGX41.43B Healthcare Biotechnology 29.01% 29.01% Onward Medical N.V
ONWD204.41M Healthcare Biotechnology -37.17% -55.89% Financière de Tubize
TUBN/A Healthcare Biotechnology 85.71% 225.88% European Medical
ALEMS20.74M Healthcare Biotechnology 6.38% -16.39% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Hyloris Pharmaceuticals SA? (e.g., ROE, Debt/Equity)
- To get a sense of Hyloris's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -21.61%, the Debt to Equity ratio from the most recent quarter is 6.08, and its Gross Profit Margin stands at -368.42%.
- What is the recent revenue and earnings growth for HYL?
- Looking at Hyloris's growth, its revenue over the trailing twelve months (TTM) was €9M. Compared to the same quarter last year (YoY), quarterly revenue grew by 7.30%, and quarterly earnings saw a YoY growth of N/A.
- How much of HYL stock is held by insiders and institutions?
- Wondering who owns Hyloris stock? Company insiders (like executives and directors) hold about 58.14% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.01%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.